Electroporation in Cell Therapy

MaxCyte has played a pivotal role in making cell therapies commercially viable, particularly with its involvement in Casgevy, the first FDA-approved gene therapy using CRISPR technology. MaxCyte has contributed to this success via its Flow Electroporation® technology, which automates and standardizes the process of introducing editing components to primary cells, enabling efficient manufacturing. This has resulted in progress in treating conditions like sickle cell disease.